Genmab AS (OCSE:GMAB) Cyclically Adjusted Revenue per Share: kr (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:GMAB Genmab AS OCSE:GMAB
100 GF Score
Price kr2,260.00
GF Value kr2,300.66
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted Revenue per Share?

Genmab AS OCSE:GMAB +0.71% 100 Cyclically Adjusted Revenue per Share is kr as of Jun. 2026. GuruFocus rates OCSE:GMAB with a GF Score™ of 100/100 and a GF Value™ of kr2,300.66 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genmab AS's adjusted revenue per share for the three months ended in Jun. 2026 was kr120.299. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted Revenue Growth Rate was 26.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 29.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 33.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genmab AS was 43.30% per year. The lowest was 29.50% per year. And the median was 36.00% per year.

As of today (2026-09-21), Genmab AS's current stock price is kr2260.00. Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr. Genmab AS's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 96.41. The lowest was 8.11. And the median was 44.18.


Genmab AS  (OCSE:GMAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 96.41. The lowest was 8.11. And the median was 44.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genmab AS Cyclically Adjusted Revenue per Share Related Terms


Genmab AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted Revenue per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OCSE:GMAB vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PS Ratio falls into.


OCSE:GMAB
100GF Score
Genmab AS OCSE:GMAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=120.299/122.9500*122.9500
=120.299

Current CPI (Jun. 2026) = 122.9500.

Genmab AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.905 100.200 7.246
201612 15.013 100.300 18.403
201703 4.050 101.200 4.920
201706 12.459 101.200 15.137
201709 5.297 101.800 6.398
201712 16.384 101.300 19.886
201803 10.974 101.700 13.267
201806 8.236 102.300 9.898
201809 9.655 102.400 11.593
201812 19.915 102.100 23.982
201903 9.576 102.900 11.442
201906 12.308 102.900 14.706
201909 16.032 102.900 19.156
201912 45.620 102.900 54.509
202003 13.562 103.300 16.142
202006 82.862 103.200 98.720
202009 26.153 103.500 31.068
202012 30.803 103.400 36.627
202103 23.960 104.300 28.244
202106 29.902 105.000 35.014
202109 34.961 105.800 40.628
202112 39.593 106.600 45.666
202203 32.127 109.900 35.942
202206 47.923 113.600 51.867
202209 62.001 116.400 65.490
202212 78.982 115.900 83.786
202303 43.050 117.300 45.124
202306 63.331 116.400 66.895
202309 71.531 117.400 74.913
202312 70.716 116.700 74.503
202403 63.099 118.400 65.524
202406 83.255 118.500 86.381
202409 86.688 118.900 89.641
202412 100.711 118.900 104.141
202503 79.268 120.200 81.082
202506 99.009 120.700 100.855
202509 105.149 121.600 106.316
202512 100.933 121.180 102.407
202603 89.602 121.670 90.545
202606 120.299 122.950 120.299

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr mean?
Genmab AS (OCSE:GMAB) has a Cyclically Adjusted Revenue per Share of kr as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted Revenue per Share too high?
Genmab AS's current Cyclically Adjusted Revenue per Share is kr. Overall, Genmab AS has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted Revenue per Share of kr can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted Revenue per Share is kr. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (OCSE:GMAB) is currently considered Fairly Valued. The stock's GF Value™ is kr2,300.66, compared to a current price of kr2,260.00 — trading 1.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr. Genmab AS's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genmab AS (OCSE:GMAB), the current Cyclically Adjusted Revenue per Share is kr as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (OCSE:GMAB) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr2,260.00 is trading 1.8% below its estimated GF Value™ of kr2,300.66. GuruFocus considers Genmab AS to be Fairly Valued.

Key valuation signals for OCSE:GMAB:

  • Cyclically Adjusted Revenue per Share: kr
  • GF Value™: kr2,300.66 vs. price of kr2,260.00 (1.8% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the OCSE:GMAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
100GF Score

Get the complete analysis for OCSE:GMAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2,260.00
Price
kr2,300.66
GF Value